proximity ligation assay
Plasma Proteome-Phenome Associations Offer Insights Into Potential Biomarkers, Disease Treatments
Researchers used blood plasma profiles and electronic health record data to find trait and disease associations, potential protein biomarkers, and potential treatment-target strategies.
Alamar Biosciences, Michael J. Fox Foundation Partner on Parkinson's Research
The partners will use Alamar's NULISA proteomics platform to develop assays for identifying biomarkers linked to neuronal synuclein diseases including Parkinson's.
The assay allows users to distinguish between target proteins present in a sample bound together in a complex and those same proteins present as free molecules.
Multiple Sclerosis Progression, Disease Response Informed by Blood-Based Immune Signatures
With targeted proteomic profiling, researchers tracked down three cellular immunological subtypes showing variable disease progression features and treatment response patterns.
Alamar Biosciences Raising $128M in Series C Funding Round
The company said it plans to use the funds to accelerate commercialization of its NULISA proteomic technology.